Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5658784 | Gastroenterology | 2017 | 28 Pages |
Abstract
Metabolic and bariatric surgery (MBS) leads to weight loss in obese individuals and reduces comorbidities such as type 2 diabetes. MBS is superior to medical therapy in reducing hyperglycemia in persons with type 2 diabetes, and has been associated with reduced mortality and incidences of cardiovascular events and cancer in obese individuals. New guidelines have been proposed for the use of MBS in persons with type 2 diabetes. We review the use of MBS as a treatment for obesity and obesity-related conditions and, based on recent evidence, propose that health care systems make the appropriate changes to increase accessibility for eligible patients.
Keywords
metabolic and bariatric surgeryVBGBPDMBSSOSGLP1RYGBHbA1cFXRRoux-en-Y gastric bypassBiliopancreatic diversionadjustable gastric bandingBariatric surgeryMetabolic surgeryType 2 diabetesbody mass indexBMIAGBMortalityHemoglobin A1cglucagon-like peptide 1Weight lossVertical banded gastroplastySleeve gastrectomy
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Josep Vidal, Ricard Corcelles, Amanda Jiménez, LÃlliam Flores, Antonio M. Lacy,